Navigation Links
Positive Results for Ophthotech's Novel Therapy for Wet AMD - Study of Anti-PDGF and Anti-VEGF Therapy Shows Significant Neovascular Regression and Enhanced Visual Outcome
Date:5/4/2009

itive to an anti-VEGF attack.

"The objective and robust response of neovascular regression is consistent with the biologic activity of E10030. I look forward to a randomized trial design to confirm the strong proof of concept data of this study," said Dr. Donald J. D'Amico, Professor and Chairman, Department of Ophthalmology, Weill Cornell Medical College, New York-Presbyterian Hospital.

"It is exciting to see our clinical trial confirm the strong preclinical data from oncology and ophthalmic studies targeting the molecules regulating pericyte and endothelial cell survival. Ophthotech will continue to devote its resources towards an accelerated development of our anti-PDGF compound," said Dr. Samir C. Patel, President and CEO of Ophthotech Corp.

Wet AMD is characterized by the abnormal growth of blood vessels (neovascularization) beneath the retina, which leak blood and fluid and can cause permanent damage to cells in the center of the retina (the macula). This form of AMD is the most severe form of the disease, and often leads to permanent vision loss.

E10030 is one of three compounds that Ophthotech is developing to treat wet and dry AMD. Additional molecular entities include an anti-C5 aptamer and volociximab, an anti-angiogenic monoclonal antibody targeting the a5B1 integrin, both currently in a Phase I study.

About anti-PDGF E10030

E10030 is an aptamer-based compound directed against PDGF-B. Pharmacology studies indicate that E10030 binds to PDGF-B with high specificity and affinity and inhibits the functions of PDGF-B both in vitro and in vivo. In preclinical studies, E10030 demonstrated the potential to regress neovascularization when used in combination with a VEGF-A inhibitor. In experiments involving models of ocular vascularization, concurrent inhibition of PDGF-B and VEGF-A signaling was superior to inhibition of the VEGF-A pathway alone.'/>"/>

SOURCE Ophthotech Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. VIA Pharmaceuticals Announces Positive Phase 2 Results of VIA-2291 in Cardiovascular Patients Using Serial MDCT Imaging of Coronary Plaque
2. Unexpected Positive Finding Expands Potential for Quigley QR333 Drug for Diabetic Neuropathy; Findings Suggest Possible Disease Modification
3. HIV positive and HIV negative patients have similar survival rates following liver transplant
4. The ALS Association's 'ALS Across America' Focuses On Staying Positive and Involved
5. Sirion Therapeutics Announces Positive Results From Interim Analysis of Phase II Trial and Receives FDA Fast Track Designation for Fenretinide
6. Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints
7. Economy Got You Down? Use The Principles Of Positive Psychology
8. Standard and Poors Raises Boston Scientifics Rating Outlook to Positive
9. Recent Industry Developments Reaffirm Positive Glucose Industry Outlook
10. Cepheid Receives Health Canada License for First On-demand Diagnostic Test for Life-threatening MRSA and S. aureus Infections From Patient Positive Blood Culture Bottles
11. Marinus Pharmaceuticals, Inc. Announces Positive Results of its Phase 2 Clinical Trial of Ganaxolone as Adjunctive Therapy in Adults With Partial Onset Seizures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... Cary, N.C. (PRWEB) October 30, 2014 ... consumer-driven health care, is increasing efforts to help people ... out-of-pocket expenses continue to increase for prescription drugs in ... provides valuable savings and resources to bridge the relationship ... , One of the biggest challenges people face today ...
(Date:10/30/2014)... October 30, 2014 Home Care Assistance ... provider of non-medical, in-home senior care, is weighing in ... brain health. , The study, performed by the University ... 60 and 78 over a week-long period and observed ... daily physical activity. By examining the structural soundness of ...
(Date:10/30/2014)... 30, 2014 REV'D Provision Co. announced ... available through a unique service called, The Feed ... empower the everyday athlete. The Feed has taken the ... created a system to pass that information on to ... is now available on The Feed!” says REV’D® marketing ...
(Date:10/30/2014)... -- When it comes to heart disease, a new study ... when they have symptoms that spell trouble. "The main ... a more severe or advanced stage of heart disease, there ... a Fulbright Scholar and research fellow at the Harvard School ... Heart and Stroke Foundation of Canada. In the study, ...
(Date:10/30/2014)... -- Eating a low-carb, high-fat diet could help control ... research. A review of five studies found ... on foods like bacon, eggs, heavy cream, butter, fish ... whose condition doesn,t improve with medication. "We need ... epilepsy whose seizures are not stopped by medications," study ...
Breaking Medicine News(10 mins):Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 2Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 3Health News:Home Care Assistance – Halton/Peel Region, a Top Provider of In-Home Care, Responds to Study Linking Exercise to Healthier Senior Brains 2Health News:Home Care Assistance – Halton/Peel Region, a Top Provider of In-Home Care, Responds to Study Linking Exercise to Healthier Senior Brains 3Health News:Nutrition Experts at TheFeed.com Get REV'D 2Health News:Nutrition Experts at TheFeed.com Get REV'D 3Health News:Women Often Ignore Signs of Heart Trouble 2Health News:High-Fat, Low-Carb Diet May Help With Tough-to-Treat Epilepsy 2Health News:High-Fat, Low-Carb Diet May Help With Tough-to-Treat Epilepsy 3
... S.C., June 2 Companion Data Services, ... International Organization for,Standardization (ISO) 9001:2000 certification, the ... CDS provides information technology and data processing ... by the federal,Centers for Medicare & Medicaid ...
... Work, Discusses Abbott,s, Contributions to Access, Innovation, Science ... June 2 Abbott (NYSE: ABT ),today ... Work,",which is available online at http://www.abbott.com/citizenship . ... innovation, science,education and the environment., Named to ...
... problem of how many identical-sized spheres can be randomly ... A team of physicists at The City College ... solution that could have implications for everything from processing ... May 29 edition of "Nature," they demonstrate that random ...
... Ignoring scientific,evidence of harm, the Louisiana State ... by the House, will require fluoride chemicals be,added ... to reduce,tooth decay. (The Advocate, 5/29/08), However, ... by,the prestigious National Research Council (NRC) reveals that ...
... Way for Approval of Merger, CHICAGO, June ... connectivity and information solutions that,physicians use to improve ... Hart-Scott-Rodino (HSR) Antitrust Improvements Act of,1976, with respect ... 2008,between Allscripts and Misys Healthcare to form Allscripts-Misys ...
... 15% of their daily calories, study finds , , MONDAY, June ... more sugary beverages and fruit juices than ever before, a ... now take in up to 15 percent of their total ... confirms previous research and suggests consumption is rising. , It,s ...
Cached Medicine News:Health News:Abbott Releases 2007 Global Citizenship Report Highlighting Strong Commitment to Access to Health Care 2Health News:Abbott Releases 2007 Global Citizenship Report Highlighting Strong Commitment to Access to Health Care 3Health News:Louisiana May Mandate Fluoridation Despite Evidence of Harm 2Health News:Antitrust Waiting Period Expires on Allscripts-Misys Merger Agreement 2Health News:Kids Gulping Down More Sugary Beverages 2Health News:Kids Gulping Down More Sugary Beverages 3
(Date:10/30/2014)...  The number of retail health clinics in ... thanks to drug store chains, according to Kalorama Information.  ... downturn, retail clinic growth had been at a standstill, ... number of retail clinics reached nearly 1,600 according to ... Overview and 2014 Consumer Survey Results .  ...
(Date:10/30/2014)... 30, 2014 China Biologic Products, Inc. (NASDAQ: ... integrated plasma-based biopharmaceutical company in China ... third quarter 2014 financial results on Wednesday, November 5, ... Company,s management will hold a conference call at 7:30 ... is 8:30 p.m., Beijing Time on November 6, 2014, ...
(Date:10/30/2014)... , October 30, 2014 ... GG hilft beim Aufbau von Kuhmilchverträglichkeit     ... für Lebensmittelallergien bei Säuglingen und Kleinkindern. Der ... bei der Ernährung der Babys bzw. deren ... sich jedoch, dass sich bei einer beträchtlichen ...
Breaking Medicine Technology:Report: Drugstore Chains Drive Retail Clinic Growth 2Report: Drugstore Chains Drive Retail Clinic Growth 3China Biologic to Report Third Quarter 2014 Financial Results 2Experten präsentieren neuste Forschungsergebnisse auf dem Allergy Day 2Experten präsentieren neuste Forschungsergebnisse auf dem Allergy Day 3
... Inc. (Nasdaq: REGN ) today announced that ... the U.S. Food and Drug Administration (FDA) for VEGF ... age-related macular degeneration (wet AMD).  Under the Prescription Drug ... review time from submission to FDA action is ten ...
... 22, 2011 ResearchDx announced today the official ... CDO. Recent FDA initiatives, such ... Co-Development Concept Paper, have spurred biopharmaceutical companies, interest ... companion diagnostics. The traditional Contract Research Organization (CRO), ...
Cached Medicine Technology:Regeneron Submits Biologics License Application to FDA for VEGF Trap-Eye for Treatment of Wet Age-Related Macular Degeneration 2Regeneron Submits Biologics License Application to FDA for VEGF Trap-Eye for Treatment of Wet Age-Related Macular Degeneration 3Regeneron Submits Biologics License Application to FDA for VEGF Trap-Eye for Treatment of Wet Age-Related Macular Degeneration 4Regeneron Submits Biologics License Application to FDA for VEGF Trap-Eye for Treatment of Wet Age-Related Macular Degeneration 5Regeneron Submits Biologics License Application to FDA for VEGF Trap-Eye for Treatment of Wet Age-Related Macular Degeneration 6Regeneron Submits Biologics License Application to FDA for VEGF Trap-Eye for Treatment of Wet Age-Related Macular Degeneration 7ResearchDx Launches Contract Diagnostics Organization (CDO) 2
... This remarkable anti-reflux valve is ... housing which prevents the valve ... when in sitting or reclining ... self-cleaning and interference free ensuring ...
... This remarkable anti-reflux valve is ... housing which prevents the valve ... when in sitting or reclining ... self-cleaning and interference free ensuring ...
The Medtronic® Resting Heart™ System offers a new approach to reducing cardiac surgery morbidity....
This adapter is 8 inches (20.3 cm) in length and features a male luer on the single leg. A soft "Y" terminates in two 1/4 inches (0.64 cm) slip connectors, one with a vent....
Medicine Products: